Skip to main content
Premium Trial:

Request an Annual Quote

Deltagen in Research Deal With Schering Institute, Introduces New Database



ENLO PARK, Calif.--Deltagen announced the signing of a DeltaSelect research agreement with Schering-Plough Research Institute to validate small molecule drug targets. Schering-Plough will provide target gene sequences to Deltagen, which will use its proprietary mammalian gene knockout and phenotypic analysis technologies to enable Schering-Plough to define each gene’s function in vivo. Financial terms of the agreement were not disclosed.

Separately, Deltagen launched its DeltaBase in vivo mammalian gene function database which enables pharmaceutical partners to access functional information on novel genes to facilitate development of new genomics-based medicines.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.